Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02172365
Other study ID # UHN 14-7493-AE
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 1, 2014
Est. completion date December 30, 2020

Study information

Verified date October 2020
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators will evaluate the outcomes of allogeneic stem cell transplantation which is the only curative treatment modality in the patients with chronic myeloid leukemia after failing tyrosine kinase inhibitor therapy. However, any update was not reported on the transplant outcomes in the patients failed TKI therapy, thus necessitating update of this data. Also, the European Group for Blood and Marrow Transplantation (EBMT) risk score is still of value, but insufficient numbers of patients have been transplanted in recent years and after TKI therapy to allow a robust reanalysis. Our study hypothesis is that allogeneic SCT treatment modality can rescue CML patients who failed TKI therapy due to resistance or to intolerance with improved survival and long-term outcomes. Also, another hypothesis will be examined if the EBMT risk score proposed pre-imatinib era can reproduce similar prognostic risk stratification of long-term outcomes in the patients treated with TKI.


Description:

Allogeneic stem cell transplantation (SCT) remains the only currently available treatment that can render patients durably molecularly negative, but the associated procedural-related morbidity and mortality remain a major deterrent. Currently the followings are accepted as reasonable indication for allogeneic SCT for CML: failure to 2nd generation tyrosine kinase inhibitor (2GTKI) after imatinib failure, 2GTKI frontline failure, or any patients meeting the criteria of failure such as development of additional cytogenetic abnormality (ACA), clonal evolution in ph neg clone, development of mutation and loss of CCyR as well as any advanced disease stage including accelerated or blastic phase. However, insufficient numbers of patients have been transplanted in recent years and after TKI therapy, thus necessitating update of this data. The EBMT risk score has been used for a decade for the decision making of transplantation in the pre-imatinib era. However, it has never been re-evaluated in a larger cohort of CML patients treated with TKIs prior to SCT then received alloSCT, thus requiring to be reanalysed for its prognostic implication on long-term survival. As mentioned above, any update was not reported on the transplant outcomes in the patients failed TKI therapy, thus necessitating update of this data. Also, the EBMT risk score2 is still of value, but insufficient numbers of patients have been transplanted in recent years and after TKI therapy to allow a robust reanalysis. This is retrospective study. The medical records will be reviewed retrospectively. The treatment outcomes such as complete cytogenetic response (CCyR), major molecular response (MMR), molecular response at 4.5 log reduction (MR4.5), treatment failure (TF), progression free survival (PFS) and overall survival (OS) will be estimated using Kaplan-Meier method. The CCR will be defined as 0% of Ph+ metaphase cells in the marrow or less than 1% by international scale using BCR-ABL1 transcript polymerase chain reaction (PCR) test. The MMR is defined as lower than or equal to a 0.1%IS of BCR-ABL1 fusion gene transcripts, and MR4.5 is defined as 0.0032%IS BCR-ABL1 transcript level, equivalent to a 4.5 log reduction of BCR-ABL1 transcript level. Time to treatment failure (TTF) is defined as the interval between allogeneic SCT and the occurrence of events that indicated that CML has relapsed including primary hematologic resistance, cytogenetic resistance, loss of CCyR, development of ABL tyrosine kinase domain mutation, clonal evolution and progression to accelerated phase (AP) or blastic crisis (BC). Death is considered as censored for TTF. Time to PFS is defined as the interval between transplantation and confirmation of progression to AP or BC or death from any cause, while OS was calculated from transplantation until the date of death from any cause or of latest follow-up. Pre-transplant characteristics and transplant procedure data will be also collected including the age, disease stage, diagnosis/transplant date, donor type and gender match. Summary of treatment outcomes following previous TKI therapies will be also collected. Post-transplant events such as graft-versus-host disease (GVHD) and progression of CML will be also collected. No study intervention. Assessment of Efficacy: Cytogenetic responses were categorized as complete (0% Ph+ cells in marrow by conventional cytogenetics), partial (1% to 34% Ph+ cells in marrow), or minor (35% to 90% Ph+ cells in marrow). A major cytogenetic response (MCyR) was defined as the sum of CCyR and partial cytogenetic response (i.e. 0% - 35% Ph+ cells in marrow). Major molecular response (MMR) was defined as lower than or equal to a 0.1%IS of BCR-ABL1 fusion gene transcripts, and molecular response 4.5 (MR4.5) was defined as 0.0032%IS BCR-ABL1 transcript level, equivalent to a 4.5 log reduction of BCR-ABL1 transcript level. Time to treatment failure (TTF) is defined as the interval between allogeneic SCT and the occurrence of events that indicated that CML has relapsed including primary hematologic resistance, cytogenetic resistance, loss of CCyR, development of ABL tyrosine kinase domain mutation, clonal evolution and progression to accelerated phase (AP) or blastic crisis (BC). Death is considered as censored for TTF. Time to PFS is defined as the interval between transplantation and confirmation of progression to AP or BC or death from any cause, while OS was calculated from transplantation until the date of death from any cause or of latest follow-up. Statistical analysis: The list of CML patients will be utilized for this retrospective study. Study ID, gender, disease characteristics at the time of diagnosis, details of treatment, detailed response to treatment, resistance or intolerance and long-term outcomes will be retrospectively reviewed. Study endpoints will be analyzed with respect to complete cytogenetic response (CCR), major/complete molecular response (MMR/CMR), loss of response, resistance, progression to advance disease and death. The cumulative incidence of CCR, MMR and CMR will be estimated and compared using the approach proposed by Gray (Gray, 1988). Overall survival will be analyzed using the Kaplan-Meier method and compared using the log-rank test. Loss of response, resistance and failure-free survival will be analyzed using the test for cumulative incidence to account for competing risk events. Baseline characteristics, including Sokal score, age, gender, disease stage, will be adopted as surrogates for further response, progression free and overall survival following transplantation. For the EBMT risk score, age of the patient, stage of the disease at transplant, time from diagnosis (<12 months vs > 12months), donor type, and donor recipient gender combination will be used for the calculation. The transplant outcomes will be compared according to the EBMT risk score. P-values of less than 0.05 will be considered statistically significant. Hazard ratios (HR) and 95% confidence intervals (CI) will be estimated with a predetermined reference risk of 1.0. The EZR software will be used for the statistical analyses.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 350
Est. completion date December 30, 2020
Est. primary completion date December 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients treated with allogeneic stem cell transplantation (SCT) since 2000 till 2013 for any of tyrosine kinase inhibitor (TKI) failure due to resistance or intolerance during chronic myeloid leukemia (CML) management with tyrosine kinase inhibitor Exclusion Criteria: - Any CML patients not previously treated with TKI therapy prior to allogeneic stem cell treatment.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada Princess Margaret Cancer Centre Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

References & Publications (5)

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26. Review. — View Citation

Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998 Oct 3;352(9134):1087-92. — View Citation

Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31;117(13):3641-7. doi: 10.1182/blood-2010-08-302679. Epub 2010 Dec 14. — View Citation

Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011 Nov 17;118(20):5697-700. doi: 10.1182/blood-2011-07-367326. Epub 2011 Sep 16. — View Citation

Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010 Mar 11;115(10):1880-5. doi: 10.1182/blood-2009-08-237115. Epub 2009 Nov 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival following allogeneic SCT for CML after TKI failure. Overall survival will be calculated from transplantation until the date of death from any cause or of latest follow-up at 3 years
Secondary Failure free survival following allogeneic SCT for CML after TKI failure Time to failure free survival is defined as the interval between transplantation and treatment failure. Treatment failure will be defined as primary hematologic resistance, cytogenetic resistance, loss of CCyR, development of ABL tyrosine kinase domain mutation, clonal evolution and progression to accelerated phase (AP) or blastic crisis (BC). at 3 years
Secondary Relapse following allogeneic SCT for CML after TKI failure Relapse will be defined as confirmation of progression to AP or BC. at 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT02057185 - Occupational Status and Hematological Disease
Recruiting NCT03326310 - Selumetinib and Azacitidine in High Risk Chronic Blood Cancers Phase 1
Recruiting NCT04621851 - Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
Completed NCT01207440 - Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Phase 2
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Active, not recruiting NCT02917720 - 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients Phase 2
Not yet recruiting NCT02883036 - Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia N/A
Withdrawn NCT01188889 - RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. Phase 1/Phase 2
Completed NCT01795716 - Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body Phase 1
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Approved for marketing NCT00905593 - Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Phase 3
Terminated NCT00573378 - Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia Phase 2
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Completed NCT00469014 - Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Phase 2
Completed NCT00257647 - Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) N/A
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT00219739 - STI571 ProspectIve RandomIzed Trial: SPIRIT Phase 3
Completed NCT06148493 - Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Completed NCT00375219 - Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Phase 2